Mineralys Therapeutics, Inc. Common Stock

Day range

$20.25 – $20.71

Open

$20.71

Prev close

$20.55

Volume

376.3K

Market cap

$1.82B

Shares out

88.41M

P/E

—

P/S

—

P/B

3.30

P/FCF

—

ROE

-63.4%

ROA

-52.3%

Debt/Equity

0.18

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentOct 19, 2026

  On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors. Ms. Peterson was appointed as a Class I director ... and was also appointed to serve as a member of the Audit Committee. Mr. Coats was appointed as a Class II director ... and was also appointed to serve as a member of the Compensation Committee.

• Executive officer appointmentAug 11, 2026

  On August 5, 2026, the Company's Board of Directors (the Board) appointed James J. Ferguson III, M.D., as the Company's new Chief Medical Officer, effective August 10, 2026, replacing David Rodman, M.D.

• Credit facilityJun 3, 2026

  On June 2, 2026 (the "Closing Date"), the Company entered into a senior secured term loan agreement (the "Loan Agreement") with BioPharma Credit PLC, as collateral agent (the "Agent"), and each of BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP, as lenders. The Loan Agreement provides for a five-year senior secured term loan, which matures on June 3, 2031 (the "Maturity Date"), for up to $500.0 million in term loans.

• Underwriting agreementJun 3, 2026

  Mineralys Therapeutics, Inc. entered into an underwriting agreement (the 'Underwriting Agreement') with BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C. (the 'Underwriters'), relating to the issuance and sale of 5,660,378 shares of the Company's common stock. The Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $25.3075 per share.

• Clinical trial resultsMar 9, 2026

  On March 9, 2026, the Company issued a press release announcing topline results from the Phase 2 Explore-OSA exploratory trial. After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the AHI, the primary endpoint. At week four, the trial demonstrated an 11.1 mmHg (p < 0.0001) and a 1.0 mmHg (p = NS) BP reduction with lorundrostat and placebo, respectively.

Days to cover

5.2

Short interest

7.81M

Avg volume

1.51M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
  positiveGlobeNewswire Inc.· Oct 22, 2026
• Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
  positiveGlobeNewswire Inc.· Oct 9, 2026
• Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
  positiveGlobeNewswire Inc.· Oct 2, 2026
• Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
  positiveGlobeNewswire Inc.· Sep 16, 2026
• Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
  positiveGlobeNewswire Inc.· Jun 8, 2026